WO2023128280A1 - 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 - Google Patents
표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 Download PDFInfo
- Publication number
- WO2023128280A1 WO2023128280A1 PCT/KR2022/018353 KR2022018353W WO2023128280A1 WO 2023128280 A1 WO2023128280 A1 WO 2023128280A1 KR 2022018353 W KR2022018353 W KR 2022018353W WO 2023128280 A1 WO2023128280 A1 WO 2023128280A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microneedle
- microspheres
- drug
- modified
- modified microspheres
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 45
- 230000014759 maintenance of location Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 29
- 239000012071 phase Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 13
- 229920002988 biodegradable polymer Polymers 0.000 claims description 12
- 239000004621 biodegradable polymer Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 11
- 239000008346 aqueous phase Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 229920003169 water-soluble polymer Polymers 0.000 claims description 10
- 239000011118 polyvinyl acetate Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 230000008020 evaporation Effects 0.000 claims description 7
- 239000007764 o/w emulsion Substances 0.000 claims description 7
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000002195 soluble material Substances 0.000 claims description 7
- 238000000935 solvent evaporation Methods 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical group 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- -1 cells Proteins 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 230000002688 persistence Effects 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 238000013268 sustained release Methods 0.000 abstract description 10
- 239000012730 sustained-release form Substances 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000001647 drug administration Methods 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 26
- 238000009472 formulation Methods 0.000 description 20
- 239000003921 oil Substances 0.000 description 17
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 229960001967 tacrolimus Drugs 0.000 description 13
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 8
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012790 adhesive layer Substances 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000000635 electron micrograph Methods 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940074052 glyceryl isostearate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Definitions
- the present invention relates to a microneedle containing surface-modified microspheres and a manufacturing method thereof, and more particularly, to a surface modification suitable for use in the treatment of diseases requiring continuous drug administration due to an excellent sustained-release effect due to enhanced retention in the body. It relates to a microneedle containing microspheres and a manufacturing method thereof.
- Drug delivery through the skin is used in various fields and forms due to its convenience of use. Drugs passing through the skin are mainly intended to be delivered to the systemic circulation through the skin, but in addition, drugs such as atopic dermatitis, acne dermatitis, and dermatological dermatological drugs are also used for the purpose of delivering to the organs of the skin itself. Despite these conveniences and functionality, there are many difficulties in delivering drugs through the skin due to the structure of the skin, so it is not easy to develop drugs that pass through the skin.
- the stratum corneum of the skin is composed of a brick structure composed of keratin-rich keratinocytes and a mortar structure filled with lipids such as ceramide, fatty acid, or wax between these keratinocytes. This structure serves as a barrier and has a very low material permeability. Only low-molecular structure components of 500 Da or less can be delivered into the skin by diffusion, and only substances with excellent lipid affinity can pass through the skin.
- the microneedle patch is a method in which several microneedles are attached to the patch and the microneedles pierce small holes on the skin surface to deliver the drug.
- the inventors of the present invention found that, in the case of microneedles prepared using microspheres whose surface was modified including a drug, the retention duration in the body was surprisingly improved and the sustained-release effect was excellent.
- the present invention was completed by confirming that it is suitable for use in the treatment of diseases requiring continuous drug administration.
- an object of the present invention is to provide microneedles including surface-modified microspheres.
- Another object of the present invention is to provide a method for manufacturing a microneedle containing surface-modified microspheres.
- Another object of the present invention is to provide a microneedle transdermal patch including the microneedle.
- a microneedle including surface-modified microspheres containing a drug is provided.
- 'surface modification' means a microsphere having a surface in which grooves such as dimple structures and wrinkles, which can be seen in golf balls, are formed on the surface of the microsphere.
- 'microspheres' are biodegradable microspheres and are carriers for delivering drugs and the like into the body.
- Biodegradable microspheres have an in vivo disappearance period depending on the degradation mechanism and decomposition rate of the biodegradable polymer, which is the main component, and the release of the drug encapsulated inside is performed over a certain period of time according to the in vivo disappearance rate of these polymers.
- the average size of the microspheres is not particularly limited, but is suitable for being inserted into a microneedle and used, and may be approximately 50 ⁇ m or less, preferably 10 ⁇ m or less.
- the surface-modified microspheres are in the form of a single emulsion, oil in water (O / W), water in oil (W / O), oil in oil (O / O), S / It may be an O (solid in oil) or S/W (soiled in water) type, preferably an oil in water (O/W) type emulsion.
- a solvent evaporation method may be used as the method for preparing the microspheres, which includes evaporating and curing the organic solvent used in the preparation of the microspheres.
- a spray drying method and sonication may be used.
- biodegradable microspheres When producing biodegradable microspheres by solvent evaporation, in the case of single emulsion oil-in-water (O/W) type microspheres, a non-polar organic solvent immiscible with water is used as an internal oil phase, and biodegradable polymers and drugs are used as above. It can be prepared by simultaneously dissolving in a non-polar organic solvent and quickly dispersing it in an aqueous phase in which a surfactant is dissolved.
- O/W emulsion oil-in-water
- the microspheres in the present invention are prepared by i) preparing an oil phase by dissolving a drug and a surface-active biodegradable polymer in an organic solvent; ii) forming an oil-in-water emulsion by mixing the oil phase with an aqueous phase in which a water-soluble polymer is dissolved; iii) evaporating the solvent from the oil-in-water emulsion to obtain surface-modified microspheres;
- 'drug' is not limited to the above drug range as long as it is a drug used for a disease requiring continuous drug administration (requiring a sustained-release effect), but is preferably a drug such as an organic compound or an inorganic compound; biological agents such as peptides, proteins, antibodies, nucleic acids, cells and genes; It may be a vaccine, a hormone, or a mixture thereof, and is preferably a water-soluble drug.
- tacrolimus was used as an example of the drug.
- Tacrolimus has the structure of Chemical Formula 1 and is used for the treatment of moderate to severe atopic dermatitis by inhibiting the production of inflammatory mediators such as IL-2 and IL-2 by inhibiting calcineurin:
- the surface-active biodegradable polymer may be naturally biodegraded in the body and thus discharged to the outside of the body. In addition, it may have a function of a surfactant capable of emulsifying drugs that are poorly soluble in water.
- a surfactant capable of emulsifying drugs that are poorly soluble in water.
- the surface-active biodegradable polymer anything derived from nature or synthetically produced may be used. It can be used as a copolymer of twin series, poloxamers, polylactate-co-glyclate (PLGA) or poly(D,L-lactic acid) (PDLA), and polyD,L-lactic acid-polycaprolactone. . In the present invention, PLGA was used as an example.
- the surface-active biodegradable polymer may have a weight average molecular weight of 5,000 to 1,000,000.
- the content of the drug and the surface-active biodegradable polymer used is not particularly limited, but a weight ratio of 0.1 to 10: 10, 0.5 to 7: 10, 3 to 7: 10, or preferably 4 to 6: 10 may be used. . In the above range, a surface in which desired grooves (dimple structures) are formed in the microspheres can be effectively formed.
- the organic solvent is not particularly limited, and dichloromethane, methanol, ethanol, chloroform, hexane, ethyl acetate, and mixtures thereof may be used, and dichloromethane is preferably used.
- the organic solvent is mixed at a mixing ratio of 1:10 to 1:30 (w/v) with respect to the mixture of the drug and the surface-active biodegradable polymer. In the above range, a surface in which desired grooves (dimple structures) are formed in the microspheres can be effectively formed.
- step ii) the oil phase and the aqueous phase are mixed.
- the water phase contains the dissolved water-soluble polymer, and the water-soluble polymer may be added to stabilize the emulsion during the emulsion-solvent evaporation process (step iii)).
- Water-soluble polymers include polyvinyl acetate (PVA), polyacrylic acid (PAA), polyvinylpyrrolidone (PVP), polyacrylamide (PAM), polyethylene oxide (PEG), polybate (Tween) and poloxamer etc. can be used.
- the water-soluble polymer may have a weight average molecular weight of 1,000 to 50,000,000. In the present invention, PVA was used as an example.
- the water-soluble polymer may be included in an amount of 0.01 to 1% by weight, preferably 0.1 to 0.5% by weight in the aqueous phase. Emulsions are effectively formed when used at the concentrations of the above conditions.
- the mixing is performed in the range of 5,000 to 12,000 rpm (1st shear), most preferably at 12,000 rpm, using a mechanical stirring means such as a homogenizer or ultrasonic waves. Mixing within the above range enables effective formation of a surface in which desired grooves (dimple structures) are formed in the microspheres.
- Evaporation in step iii) is a process of evaporating the organic solvent of the oil phase formed in the aqueous phase, which is a continuous phase.
- Evaporation may be performed with stirring, and stirring may include mechanical stirring, wherein the stirring speed is in the range of 800 to 1,000 rpm (2nd shear), most preferably 1,000 rpm. Stirring within the above range appropriately controls the rate of evaporation so that grooves (dimple structures) can be well formed on the surface of the microspheres.
- Microspheres are formed through evaporation, which are dispersed in water, which is a continuous phase. Microspheres can be obtained simply by filtering. If necessary, an impurity removal process such as washing, a centrifugation process, and a drying process may be additionally performed.
- the material of the microneedle in order to deliver the drug-containing surface-modified microspheres into the skin, the material of the microneedle must be soluble that can be disintegrated by moisture in the skin, and must be biocompatible to be absorbed or decomposed without side effects in the body. It is preferable to be made of a material having strength capable of penetrating the skin after being manufactured.
- the microneedle of the present invention is soluble, that is, it is soluble in water that dissolves in body fluids within the skin.
- alginic acid As the soluble material forming the microneedle of the present invention, alginic acid, chitosan, collagen, gelatin, hyaluronic acid, chondroitin (sulfate), dextran (sulfate), fibrin, agarose, pullulan, cellulose, polyvinylpyrrolidone ( PVP), polyethylene glycol (PEG), polyvinyl alcohol (PVA), vinylpyrrolidone-vinyl acetate copolymer, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, polyalcohol, Cyclodextrin, dextrin, trehalose, glucose, fructose, starch, sucrose, glucose, maltose, lactose, lactulose, fructose, turanose, melitose, melezitose, dextran, sorbitol, mannitol and xylit
- the microneedle of the present invention may further include a plasticizer, a surfactant, and a preservative.
- plasticizer for example, polyols such as ethylene glycol, propylene glycol, dipropylene glycol, butylene glycol, and glycerin may be used alone or in combination, but are not limited thereto.
- surfactant for example, PEG-8 glyceryl isostearate, PEG-10 glyceryl isostearate, PEG-15 glyceryl isostearate, PEG-20 hydrogenated castor oil, PEG-30 hydrogenated castor oil , PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-80 hydrogenated castor oil, ceteareth-12, etc. may be used alone or in combination, but are not limited thereto.
- preservatives include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, paraoxybenzoic acid, (iso)propyl paraoxybenzoic acid, (iso)butylchlorobutanol (chlorobutol), benzalkonium chloride, benzentonium chloride, phenol ( p), cresol, chlorocresol, dihydroacetic acid, sodium dihydroacetate, sorbic acid, potassium sorbate, sodium sorbate, benzoic acid, sodium benzoate, etc. may be used alone or in combination, but are not limited thereto.
- the shape of the needle part of the microneedle according to the present invention may be a conical shape, a pyramidal shape, a spear shape, a short-headed wedge shape, a blade shape, and the like, and they should have a common shape capable of penetrating the skin.
- a microneedle having a structurally stable pyramidal needle part was adopted.
- the microneedle 10 of the present invention may include a needle portion 11 and a mattress layer 12 .
- the needle portion 11 has a shape that facilitates penetration into the skin as defined above.
- the length of the needle part 11 is 500 to 1000 ⁇ m, preferably 750 ⁇ m.
- the mattress layer 12 has a thickness of 0.1 to 1 mm, preferably 0.1 to 0.3 mm.
- the needle portion and the mattress layer contain (contain) surface-modified microspheres containing a drug.
- the microneedle patch 100 of the present invention is made to be used by attaching the microneedle patch to the skin by laminating the adhesive layer 20 on one side of the mattress layer 12.
- the portion of the adhesive layer other than the portion where the microneedle 10 contacts the adhesive layer 20 is less than 50% of the total area of the adhesive layer.
- the microneedle patch 100 may also include a protective film 30 on the pressure-sensitive adhesive layer.
- a method for manufacturing the microneedle is provided.
- the soluble material, drug, surface modification, and microspheres are as defined above.
- the first solution may further include a plasticizer, a surfactant, a preservative, and the like.
- Plasticizers, surfactants, preservatives and the like are as defined above.
- step b) The method for preparing the surface-modified microspheres of step b) is as defined above.
- step c 0.1 to 20 parts by weight of the surface-modified microspheres is mixed with 100 parts by weight of the first solution.
- the surface-modified microspheres containing the drug must be evenly distributed in the microneedles, after mixing the first solution and the surface-modified microspheres, they are strongly homogenized by vortexing, etc., so that the microspheres in the mixed solution are stable and uniform. to be dispersed
- Conditions such as temperature used for manufacturing the microneedle are not particularly limited as long as the soluble material or the surface-modified microspheres can be sufficiently dissolved or mixed without being decomposed or deformed.
- step d) the step of filling the microneedle mold with the mixed solution is a method of applying the mixed solution and then leaving it, a method of injecting the mixed solution using a centrifuge, a method of injecting the mixed solution by removing air from the inside using a vacuum , a method of injecting a mixed solution by applying pressure, etc. can be used.
- step e) It may be dried at room temperature, and may be dried at room temperature to 80 ° C using a hot air dryer or the like, but is not limited thereto.
- microneedle transdermal microneedle including the surface-modified microspheres containing the drug or microneedle including the surface-modified microspheres containing the drug prepared by the above manufacturing method patch is provided.
- the microneedle transdermal patch can be used for treating and improving atopic dermatitis and acne.
- microneedle including the surface-modified microspheres containing the drug according to the present invention is useful for the treatment of diseases requiring continuous drug administration because it has an excellent sustained-release effect due to enhanced retention in the body.
- 1a and 1b are electron micrographs of the microspheres prepared in Preparation Example 1.
- 3a is a result of measuring the dispersion stability of microspheres containing tacrolimus surface-modified with a dimple structure according to the present invention using LUMiSizer.
- Figure 3b is a result of measuring the dispersion stability of microspheres containing tacrolimus having a conventional smooth surface structure using LUMiSizer.
- FIGS. 4A and 4B are schematic views of an example of a microneedle and a microneedle patch according to the present invention.
- FIG. 5 is an electron micrograph of a microneedle according to the present invention.
- FIG. 6 is a result of analyzing the content of tacronimus remaining under the skin over time after the microneedle patch according to the present invention was attached to the rat skin.
- Microspheres containing tacrolimus were prepared through an oil-in-water (O/W) emulsion solvent evaporation method. Conditions for formulation composition, oil phase, aqueous phase, solvent composition, homogenizer, and mechanical stirrer were performed as shown in Table 1 below.
- dichloromethane was added to 120 mg of tacronimus and 300 mg of PLGA 503H (Evonik Ltd., Germany) in the same amount as in Tables 1 and 2, dissolved to prepare an oil phase, and then 0.5 to 1% polyvinyl alcohol. (PVA 500, OCI Company, Ltd., Korea)
- the aqueous phase of the solution was mixed with a homogenizer for 2 minutes under the conditions shown in Table 1 to form an oil-in-water emulsion.
- the organic solvent was evaporated to form microspheres.
- a centrifuge X 820g was run for 5 minutes, washed three times with distilled water, and freeze-dried for 2 days to obtain powdery particles.
- the formulations in Table 1 were additionally prepared by changing the manufacturing conditions.
- the PVA content in the aqueous phase was increased to 1.5%, but there was no effect.
- Surface-modified microspheres with a dimple structure were prepared.
- the amount of solvent (DCM) in the oil phase was reduced to 10 ml, and microspheres surface-modified with a dimple structure were prepared.
- the agitation speed (2nd shear) was increased to 1,000 rpm, and microspheres surface-modified with a dimple structure were produced.
- microspheres surface-modified into a dimple structure were produced, and when microspheres of Formulations 8 and 9 were prepared by increasing the agitation speed (2nd shear) to 800-1,000 rpm in the evaporation step, the surface was modified into a dimple structure microspheres were prepared.
- the preferred conditions for preparing microspheres surface-modified with a dimple structure are the mixing of the oil phase and the aqueous phase in the range of 5,000 to 15,000 rpm (1st shear), most preferably 12,000 rpm
- stirring is performed in the range of 800 to 1,000 rpm (2nd shear), most preferably at 1,000 rpm, and the organic solvent is 1:10 to 1:10 for the mixture of drug and surface-active biodegradable polymer in the oil phase.
- Test Example 1 Analysis of dispersion stability of surface-modified microspheres
- the surface-modified microspheres (dimple structure) according to the present invention have high dispersion stability due to the low Instability Index result value.
- Microneedles of Example 1 and Comparative Example 1, respectively, including surface-modified (dimple structure) microspheres (Formulation 7) and smooth surface microspheres (Formulation 9) containing tacrolimus prepared in Preparation Example 1 were prepared.
- the mold was placed in a desiccator and maintained at a reduced pressure of -0.04 Mpa for 30 minutes, followed by drying in a hot air dryer at 50°C for 1 hour and 30 minutes.
- the dried microneedles were collected using adhesive tape, and the edges were rounded using scissors to match the shape of the patch (FIG. 4B), and an electron micrograph of the completed microneedle was taken and shown in FIG. 5.
- Test Example 2 Analysis of drug retention in the body under the skin
- the hairless back skin of a 6-week-old male SD-rat was taken and mounted in an in-vitro Franz cell permeation test, and the microneedle patches of Example 1 and Comparative Example 1 prepared in Preparation Example 2 were attached, and after 0.5 minutes had elapsed, microneedle patches were attached.
- the back skin was taken at sampling times of 0, 1, 12, and 24 hours, respectively, and the surface was wiped with an alcohol swab, shaken and extracted with HPLC mobile phase, and the supernatant of the extract was taken and subjected to HPLC quantitative analysis, and the results are shown in Tables 7 and 7. shown in Figure 6.
- Example 1 Comparative Example 1 Mean ( ⁇ g/cm 2 ) STDEV Mean ( ⁇ g/cm 2 ) STDEV Early 5.6 1.2 4.8 0.6 1 hours 6.7 0.4 0.9 0.2 12 hours 5.8 0.4 0.9 0.3 24 hours 3.3 0.7 0.3 0.1
- the inserted microspheres can be removed from the subcutaneous layer due to skin elasticity.
- the dimple-structured microspheres of Example 1 do not escape from the subcutaneous surface compared to the smooth surface microspheres of Comparative Example 1 due to surface roughness, confirming that the retention in the body is high. do. Therefore, it can be seen that the microneedle containing the surface-modified microspheres according to the present invention has improved retention in the body, and as a result, the sustained effect (sustained-release effect) of the drug in the microspheres is achieved.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
제형 | No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
Tacrolimus (mg) | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | |
PLGA 503H (mg) | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | |
Oil phase | DCM (mL) | 15 | 15 | 15 | 10 | 10 | 10 | 10 | 10 | 10 |
Water phase | PVA solution (w/v, %) | 0.5%, 600 mL | 0.5%, 600 mL | 0.5%, 600 mL | 0.5%, 600 mL | 0.5%, 600 mL | 0.5% 600 mL | 0.5% 600 mL | 0.5%, 600 mL | 0.5%, 600 mL |
1st Shear (Homogenizer) |
Homogenizer (rpm) | 10,000 | 10,000 | 5,000 | 10,000 | 12,000 | 15,000 | 12,000 | 12,000 | 12,000 |
2nd Shear (Mechanical stirrer) |
Stirring rate (rpm) | 1000 | 500 | 1000 | 1000 | 500 | 800 | 1000 | 100 | 500 |
제형 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
Dv10 (μm) | 1.13 | 1.2 | 1.14 | 1 | 1.15 | 1.69 | 1.21 | 0.196 | 0.191 |
Dv50 (μm) | 3.06 | 3.15 | 7.06 | 6.77 | 4.62 | 6.84 | 5.96 | 5.81 | 4.34 |
Dv90 (μm) | 6.46 | 7.39 | 14.8 | 12.6 | 10.4 | 11.11 | 10.6 | 20.5 | 13.4 |
Span | 1.741 | 1.96 | 1.94 | 1.71 | 2.00 | 1.38 | 1.57 | 3.50 | 2.86 |
수율 (%) | 69 | 64 | 55.4 | 69.9 | 38.5 | 51.0 | 59.8 | 37.6 | 45.7 |
제형 7 | |
수율 (%) | > 40% |
Entrapment efficiency (%) | 18.77 ± 0.79 |
Dv10 (μm) | 0.307 |
Dv50 (μm) | 8.03 |
Dv90 (μm) | 20.6 |
Span | 2.531 |
미립구 | Instability Index | Mean RCA in g | Time in s |
제형7 | 0.234 | 11.63 | 2,991 |
제형9 | 0.261 | 11.62 | 3,002 |
측정조건(TA.XT Plus Texture analyser) | |
Mode | Compression |
Pre-Test Speed | 1.00mm/sec |
Test Speed | 0.1mm/sec |
Post-Test Speed | 10.00 mm/sec |
Distance | 0.800 mm |
Trigger Force | 0.049 N |
Needle당 강도 (N/개) | ||||
No. | 강도 (N) | 평균 | STD | |
실시예 1 | 1 | 2.01 | 2.02 | 0.07 |
2 | 1.95 | |||
3 | 2.09 |
샘플링 시간 | 실시예 1 | 비교예 1 | ||
평균 (㎍/cm2 ) | STDEV | 평균 (㎍/cm2) | STDEV | |
초기 | 5.6 | 1.2 | 4.8 | 0.6 |
1시간 | 6.7 | 0.4 | 0.9 | 0.2 |
12시간 | 5.8 | 0.4 | 0.9 | 0.3 |
24시간 | 3.3 | 0.7 | 0.3 | 0.1 |
Claims (18)
- 약물을 함유하는 표면개질 미립구를 포함하는 마이크로니들로,상기 표면개질 미립구는 딤플(dimple) 구조 또는 주름의 홈이 생성되어 있는 표면을 갖는 생분해성 미립구이며,상기 마이크로니들은 피부 내에서 용해성이고 증진된 체내 체류 지속성을 갖는 것인 마이크로니들.
- 제 1항에 있어서, 약물은 유기화합물 또는 무기화합물의 약제, 펩타이드, 단백질, 항체, 핵산, 세포, 유전자, 백신 및 이들의 혼합물로부터 선택되는 하나 이상인 것인 마이크로니들.
- 제 2항에 있어서, 상기 약물은 물에 난용성인 것인 마이크로니들.
- 제 1항에 있어서, 상기 미립구의 평균 크기는 50㎛ 이하인 것인 마이크로니들.
- 제 1항에 있어서, 상기 미립구는 용매 증발법, 분무건조법 및 초음파 파쇄법 중 어느 하나의 방법에 의해 제조되는 것인 마이크로니들.
- 제 5항에 있어서, 용매 증발법은,i) 약물 및 계면활성 생분해성 고분자를 유기 용매에 용해하여 유상을 준비하는 단계;ii) 수용성 고분자가 용해된 수상에 상기 유상을 혼합하여 수중유 에멀젼을 형성하는 단계; 및iii) 상기 수중유 에멀젼에서 용매를 증발시켜 표면이 개질된 미립구를 얻는 단계를 포함하는 것인 마이크로니들.
- 제 6항에 있어서, 계면활성 생분해성 고분자는 트윈계열, 폴록사머류, 폴리락테이트-코-글라이클레이트(PLGA), 폴리(D,L-락트산)(PDLA), 및 폴리D,L-락트산-폴리카프로락톤의 공중합체 중 어느 하나이고, 수용성 고분자는 폴리비닐아세테이트(PVA), 폴리아크릴산(PAA), 폴리비닐피롤리돈(PVP), 폴리아크릴아마이드(PAM), 폴리에틸렌옥사이드(PEG), 폴리스베이트(Tween) 및 폴록사머(Poloxamer) 중 어느 하나인 것인 마이크로니들.
- 제 6항에 있어서, 단계 ii)에서 혼합은 5,000 ~ 12,000rpm으로 수행되고, 단계 iii)에서 증발은 800 ~ 1,000rpm의 교반하에 수행되는 것인 마이크로니들.
- 제 1항에 있어서, 마이크로니들을 형성하는 용해성 재료는 알긴산, 키토산, 콜라겐, 젤라틴, 히알루론산, 콘드로이친(설페이트), 덱스트란(설페이트), 피브린, 아가로스, 풀루란, 셀룰로오스, 폴리비닐피롤리돈(PVP), 폴리에틸렌글리콜(PEG), 폴리비닐알콜(PVA), 비닐피롤리돈-비닐아세테이트 공중합체, 히드록시프로필 셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 나트륨 카르복시메틸셀룰로오스, 폴리알콜, 시클로덱스트린, 덱스트린, 트레할로스, 포도당, 과당, 녹말, 수크로스, 글루코스, 말토스, 락토스, 락툴로스, 프락토스, 투라노스, 멜리토스, 멜레지토스, 덱스트란, 솔비톨, 만니톨, 크실리톨, 이들의 유도체 및 이들의 혼합물로 이루어진 군으로부터 선택되는 어느 하나인 것인 마이크로니들.
- 제 9항에 있어서, 마이크로니들을 형성하는 용해성 재료는 알긴산 및 트레할로스의 혼합물인 것인 마이크로니들.
- 제 1항에 있어서, 마이크로니들의 니들부의 모양은 통상 원뿔형, 피라미드형, 스피어형, 단두형 쐐기형, 칼날형 중 어느 하나인 것인 마이크로니들.
- 제 1항에 있어서, 마이크로니들의 니들부의 길이는 500 내지 1000 ㎛인 것인 마이크로니들.
- 제 1항에 따른 마이크로니들의 제조방법으로, 상기 방법은a) 용해성 재료를 물에 용해하여 제1 용액을 형성하는 단계,b) 약물을 함유하는 표면개질 미립구를 제조하는 단계,c) 제1 용액과 상기 표면개질 미립구를 혼합하고 균질화시켜 혼합 용액을 만드는 단계,d) 음각의 마이크로니들 몰드에 상기 혼합 용액을 채우는 단계, 및e) 채워진 혼합 용액을 건조시켜 몰드에서 분리하는 단계를 포함하는 것인 방법.
- 제 13항에 있어서, 단계 c)에서 제1 용액 100 중량부에 대하여 표면개질 미립구를 0.1 ~ 20 중량부로 혼합하는 것인 마이크로니들의 제조방법.
- 제 13항에 있어서, 상기 표면개질 미립구는 딤플 구조의 홈이 생성되어 있는 표면을 갖는 생분해성 미립구이며, 상기 약물은 타크로니무스인 것인 마이크로니들의 제조방법.
- 제 1항에 따른 약물을 함유하는 표면개질 미립구를 포함하는 마이크로니들을 포함하는 마이크로니들 경피 패치.
- 제 16항에 있어서, 상기 약물은 타크로니무스인 마이크로니들 경피 패치.
- 제 17항에 있어서, 아토피성 피부염 또는 여드름 치료 및 개선용인 마이크로니들 경피 패치.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280008593.9A CN116782887A (zh) | 2021-12-31 | 2022-11-18 | 包含表面改质微球的微针及其制造方法 |
US18/268,812 US20240198070A1 (en) | 2021-12-31 | 2022-11-18 | Microneedles comprising surface-modified microspheres and method of preparing the same |
JP2023541116A JP2024504918A (ja) | 2021-12-31 | 2022-11-18 | 表面改質ミクロスフェアを含むマイクロニードルおよびその製造方法 |
EP22908812.5A EP4252740A4 (en) | 2021-12-31 | 2022-11-18 | MICRONEEDLE WITH SURFACE-MODIFIED MICROSPHERES AND MANUFACTURING PROCESS THEREFOR |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0194179 | 2021-12-31 | ||
KR20210194179 | 2021-12-31 | ||
KR1020220143143A KR102598159B1 (ko) | 2021-12-31 | 2022-10-31 | 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 |
KR10-2022-0143143 | 2022-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023128280A1 true WO2023128280A1 (ko) | 2023-07-06 |
Family
ID=86999480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/018353 WO2023128280A1 (ko) | 2021-12-31 | 2022-11-18 | 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240198070A1 (ko) |
EP (1) | EP4252740A4 (ko) |
JP (1) | JP2024504918A (ko) |
KR (1) | KR20230110465A (ko) |
WO (1) | WO2023128280A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110137254A1 (en) * | 2009-11-10 | 2011-06-09 | Dick Scholten | Manufacturing method for a porous microneedle array and corresponding porous microneedle array and corresponding substrate composite |
KR101549086B1 (ko) * | 2014-11-10 | 2015-09-02 | 주식회사 스몰랩 | 마이크로 니들 및 마이크로 니들 패치 |
KR20160122051A (ko) * | 2015-04-13 | 2016-10-21 | 주식회사 엘지생활건강 | 신경전달물질을 조절하는 펩타이드의 신경세포 전달용 용해성 미세바늘 |
KR101746024B1 (ko) * | 2016-07-14 | 2017-06-12 | 경북대학교 산학협력단 | 다공성 코팅층이 코팅된 마이크로니들과 이것의 제조 방법 그리고 마이크로니들이 구비된 마이크로니들패치 |
KR20190080549A (ko) * | 2017-12-28 | 2019-07-08 | 주식회사 더마젝 | 미백용 용해성 마이크로니들 및 그 제조방법 |
KR102234446B1 (ko) | 2020-07-30 | 2021-04-01 | 주식회사 바이오셀트란 | 피부투과성 재조합 뉴로펩타이드 콤플렉스가 함유된 용해성 마이크로니들 패치 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105998463A (zh) * | 2016-06-24 | 2016-10-12 | 赵晶晶 | 一种治疗骨关节炎的微针透皮给药贴及其制备方法 |
CN110917176B (zh) * | 2018-08-31 | 2021-03-30 | 中科微针(北京)科技有限公司 | 一种可植入型缓释微针贴片及其制备方法 |
-
2022
- 2022-11-18 US US18/268,812 patent/US20240198070A1/en active Pending
- 2022-11-18 EP EP22908812.5A patent/EP4252740A4/en active Pending
- 2022-11-18 JP JP2023541116A patent/JP2024504918A/ja active Pending
- 2022-11-18 WO PCT/KR2022/018353 patent/WO2023128280A1/ko active Application Filing
-
2023
- 2023-07-10 KR KR1020230089181A patent/KR20230110465A/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110137254A1 (en) * | 2009-11-10 | 2011-06-09 | Dick Scholten | Manufacturing method for a porous microneedle array and corresponding porous microneedle array and corresponding substrate composite |
KR101549086B1 (ko) * | 2014-11-10 | 2015-09-02 | 주식회사 스몰랩 | 마이크로 니들 및 마이크로 니들 패치 |
KR20160122051A (ko) * | 2015-04-13 | 2016-10-21 | 주식회사 엘지생활건강 | 신경전달물질을 조절하는 펩타이드의 신경세포 전달용 용해성 미세바늘 |
KR101746024B1 (ko) * | 2016-07-14 | 2017-06-12 | 경북대학교 산학협력단 | 다공성 코팅층이 코팅된 마이크로니들과 이것의 제조 방법 그리고 마이크로니들이 구비된 마이크로니들패치 |
KR20190080549A (ko) * | 2017-12-28 | 2019-07-08 | 주식회사 더마젝 | 미백용 용해성 마이크로니들 및 그 제조방법 |
KR102234446B1 (ko) | 2020-07-30 | 2021-04-01 | 주식회사 바이오셀트란 | 피부투과성 재조합 뉴로펩타이드 콤플렉스가 함유된 용해성 마이크로니들 패치 |
Non-Patent Citations (1)
Title |
---|
See also references of EP4252740A4 |
Also Published As
Publication number | Publication date |
---|---|
JP2024504918A (ja) | 2024-02-02 |
KR20230110465A (ko) | 2023-07-24 |
US20240198070A1 (en) | 2024-06-20 |
EP4252740A4 (en) | 2024-09-04 |
EP4252740A1 (en) | 2023-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102598159B1 (ko) | 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 | |
WO2020043167A1 (zh) | 一种可快速植入型缓释微针贴片及其制备方法 | |
KR101148470B1 (ko) | 구강점막용 펜타닐 함유 패치 | |
WO2010024615A2 (ko) | 용매교류증발법에 의한 서방출성 미립구의 제조방법 | |
EP0330180A1 (en) | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same | |
WO1999039700A1 (en) | Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process | |
WO2016013755A1 (ko) | 레티놀 또는 레티놀 유도체를 함유하는 마이크로니들 | |
CN103520006A (zh) | 一种柔性纳米脂质体及其制备方法和应用 | |
WO2016163753A1 (ko) | 단백질 또는 펩타이드 전달용 용해성 마이크로니들 | |
WO2022005071A1 (ko) | 미세섬유 네트워크 구조체를 함유한 마이크로니들 | |
CN103520007A (zh) | 皮肤活性因子类柔性纳米脂质体及其制备方法和应用 | |
MXPA01005540A (es) | Microesferas de liberacion prolongada para encapsular analogos de la hormona liberadora de la hormona luteinizante y metodo para prepararlas. | |
CN110787152A (zh) | 一种促进皮肤吸收能力低药物的透皮凝胶贴剂及制备方法 | |
WO2009134091A2 (ko) | 난용성 약물을 함유하는 균일한 크기의 고분자 나노입자 제조방법 | |
WO2023128280A1 (ko) | 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 | |
KR102598161B1 (ko) | 호르몬 함유 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 | |
WO2017155267A1 (ko) | 자가 조립 나노입자 방출형 용해성 마이크로니들 구조체 및 그 제조방법 | |
WO2016163752A1 (ko) | 난용성 약물 전달용 용해성 마이크로니들 | |
WO2019088315A1 (ko) | 탈모 방지제 및 발모 치료제 전달을 위한 용해성 미세바늘 패치 | |
WO2023128281A1 (ko) | 호르몬 함유 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 | |
CN116782887A (zh) | 包含表面改质微球的微针及其制造方法 | |
CN113288884A (zh) | 含有壳聚糖的药物制剂、药物透皮贴剂及其制备方法 | |
KR102494542B1 (ko) | 아토피 피부염에서 가려움증 치료제를 함유한 용해성 미세바늘 패치 | |
KR102399484B1 (ko) | 건선 치료제 전달을 위한 용해성 미세바늘 패치 | |
KR102652671B1 (ko) | 피임 마이크로니들용 미립구 조성물 및 이를 포함한 피임 마이크로니들 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 202280008593.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023541116 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18268812 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022908812 Country of ref document: EP Effective date: 20230627 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22908812 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |